Search

Displaying results 8521 - 8530 of 9686 in total
  1. Drug

    Cefmenoxime

    go.drugbank.com/drugs/DB00267
    Approved

    It is reported to exhibit high activity against a wide variety of gram-positive and gram-negative bacteria. … Cefmenoxime is a novel broad-spectrum and third-generation cephalosporin antibiotic that is typically used in the treatment of female gynecologic and obstetric infections.

  2. Drug

    Chlorotrianisene

    go.drugbank.com/drugs/DB00269
    ApprovedWithdrawn

    A powerful synthetic, non-steroidal estrogen. [PubChem]

  3. Drug

    Argatroban

    go.drugbank.com/drugs/DB00278
    ApprovedInvestigational

    Argatroban is a direct, selective thrombin inhibitor. … Argatroban is a non-heparin anticoagulant shown to both normalize platelet count in patients with HIT and prevent the formation of thrombi.

    Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index
  4. Drug

    Tranexamic acid

    go.drugbank.com/drugs/DB00302
    ApprovedInvestigational

    It possesses a similar mechanism of action to [aminocaproic acid] but is approximately 10-fold more potent. … Tranexamic acid is a synthetic derivative of [lysine] used as an antifibrinolytic in the treatment and prevention of major bleeding.

  5. Drug

    Methamidophos

    go.drugbank.com/drugs/DB14972
    Experimental

    Methamidophos is under investigation in clinical trial NCT03223753 (Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia in First Remission).

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Pimodivir

    go.drugbank.com/drugs/DB14974
    Investigational

    Pimodivir is under investigation in clinical trial NCT02658825 (A Study to Evaluate the Effect of JNJ-63623872 on Cardiac Repolarization Interval in Healthy Participants).

  7. Drug

    Voxelotor

    go.drugbank.com/drugs/DB14975
    Approved

    Voxelotor is a novel hemoglobin S polymerization inhibitor for the treatment of sickle cell disease. … This is a genetically inherited condition most prevalent in the Middle East, Africa, and certain parts of India.

  8. Drug

    Cimlanod

    go.drugbank.com/drugs/DB14983
    Investigational

    Cimlanod is under investigation in clinical trial NCT02819271 (A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers)

  9. Drug

    Casimersen

    go.drugbank.com/drugs/DB14984
    ApprovedInvestigational

    a six-membered morpholino ring, and the phosphodiester links between nucleotides are replaced with a phosphorodiamidate linkage. … A related, albeit a less severe, form of muscular dystrophy known as Becker muscular dystrophy (BMD) is characterized by shortened and partially functional dystrophin protein production.

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    Fitusiran

    go.drugbank.com/drugs/DB15002
    ApprovedInvestigational

    Fitusiran is an antithrombin-directed double-stranded small interfering ribonucleic acid (siRNA) that is covalently linked to a ligand containing a triantennary N-acetylgalactosamine (GalNAc) moiety. … [L52860] Fitusiran was first approved by the FDA on March 28, 2025, as routine prophylaxis therapy to prevent or reduce the frequency of bleeding episodes associated with hemophilia A or B.